Literature DB >> 25630419

Multidisciplinary Treatment of Cystic Fibrosis-Related Recurrent Pyogenic Cholangitis (CF-RPC).

James Buxbaum1, Nancy Nguyen, Sujit Kulkarni, Suzanne Palmer, Adupa Rao, Robert Selby.   

Abstract

BACKGROUND: As the survival of cystic fibrosis patients improves due to better treatment of its pulmonary manifestations, the management of hepatobiliary complications becomes increasingly vital. While focal biliary cirrhosis is common, large duct manifestations are less frequently encountered.
METHODS: We prospectively evaluated cases of large bile duct disease in a large adult cystic fibrosis practice at the Keck Hospital of the University of Southern California.
RESULTS: Over a 5-year period, six patients presented with cholangiectasia, hepatolithiasis, and strictures. Their clinical presentation and course closely resembled recurrent pyogenic cholangitis (RPC). Treatment of cholangitis and strictures was primarily by endoscopic retrograde cholangiopancreatography, but major hepatobiliary surgery following pulmonary optimization was required in 33 %.
CONCLUSION: In adult populations, CF-RPC may not be as unusual as previously reported and recognition allows optimal endoscopic, medical, and surgical management.

Entities:  

Mesh:

Year:  2015        PMID: 25630419     DOI: 10.1007/s10620-015-3532-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  19 in total

1.  The changing epidemiology of recurrent pyogenic cholangitis.

Authors:  C M Lo; S T Fan; J Wong
Journal:  Hong Kong Med J       Date:  1997-09       Impact factor: 2.227

Review 2.  A review of abdominal organ transplantation in cystic fibrosis.

Authors:  Brandy R Lu; Carlos O Esquivel
Journal:  Pediatr Transplant       Date:  2010-10-14

Review 3.  An overview of international literature from cystic fibrosis registries: 1. Mortality and survival studies in cystic fibrosis.

Authors:  R Buzzetti; D Salvatore; E Baldo; M P Forneris; V Lucidi; D Manunza; I Marinelli; B Messore; A S Neri; V Raia; M L Furnari; G Mastella
Journal:  J Cyst Fibros       Date:  2009-05-06       Impact factor: 5.482

4.  Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.

Authors:  C Colombo; P M Battezzati; M Podda; N Bettinardi; A Giunta
Journal:  Hepatology       Date:  1996-06       Impact factor: 17.425

5.  Current management of recurrent pyogenic cholangitis.

Authors:  C A Cosenza; F Durazo; S C Stain; N Jabbour; R R Selby
Journal:  Am Surg       Date:  1999-10       Impact factor: 0.688

Review 6.  Recurrent pyogenic cholangitis: from imaging to intervention.

Authors:  Eric J Heffernan; Tony Geoghegan; Peter L Munk; Stephen G Ho; Alison C Harris
Journal:  AJR Am J Roentgenol       Date:  2009-01       Impact factor: 3.959

7.  Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome.

Authors:  Carla Colombo; Pier Maria Battezzati; Andrea Crosignani; Alberto Morabito; Diana Costantini; Rita Padoan; Annamaria Giunta
Journal:  Hepatology       Date:  2002-12       Impact factor: 17.425

8.  Gallstones in Western Japan. Factors affecting the prevalence of intrahepatic gallstones.

Authors:  M Nagase; Y Hikasa; R D Soloway; H Tanimura; M Setoyama; H Kato
Journal:  Gastroenterology       Date:  1980-04       Impact factor: 22.682

Review 9.  Hepatobiliary complications of cystic fibrosis.

Authors:  Andrew P Feranchak
Journal:  Curr Gastroenterol Rep       Date:  2004-06

10.  Cystic fibrosis transmembrane conductance regulators (CFTR) in biliary epithelium of patients with hepatolithiasis.

Authors:  Hong-Ja Kim; Sung-Koo Lee; Myung-Hwan Kim; Jeoung-Min Son; Sang-Soo Lee; Ju-Sang Park; Dong-Wan Seo; Young-Il Min
Journal:  Dig Dis Sci       Date:  2002-08       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.